Trial Profile
A double-blind, placebo-controlled crossover study to assess the pharmacokinetic profile and the physiological and behavioral effects of repeat rivastigmine (Exelon) administration in young healthy male volunteers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Aug 2015
Price :
$35
*
At a glance
- Drugs Rivastigmine (Primary)
- Indications Alzheimer's disease
- Focus Pharmacodynamics
- Acronyms RIVA-1
- 22 Mar 2008 New trial record.